IndustryCompany release

Clearmind Medicine's psychedelic-derived PTSD compound patent application published in Hong Kong

Clearmind Medicine Inc. (CMND) · Thu 19 Nov 2026

Clearmind Medicine says a Hong Kong application covering psychedelic-derived compounds for PTSD and other mental health disorders has been published; no patent has yet been granted.

Clearmind Medicine (Nasdaq: CMND) announced on 19 November 2026 that a patent application filed in Hong Kong has been published. The application covers psychedelic-derived compounds intended for post-traumatic stress disorder (PTSD) and other mental health disorders.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Clearmind Medicine Inc. ↗

Article written by VigiEye from the official source (Clearmind Medicine Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →